|
See related Octostim inj information |
|
|
|
Manufacturer |
Ferring |
|
Distributor |
Hong Kong: Ferring |
|
Contents |
Desmopressin acetate |
|
Indications |
Shortening or normalization of prolonged bleeding time prior to an invasive operation; prolonged bleeding time as a consequence of congenital or drug-induced thrombocyte dysfunction, uraemia, cirrhosis of the liver or unknown aetiology. Therapeutic control of bleeding & bleeding prophylaxis in patients w/ haemophilia A & von Willebrand's disease.
Click to view Octostim detailed prescribing infomation |
|
Dosage |
0.3 mcg/kg SC or IV infusion over 15-30 min. If a positive effect is obtained, the initial dose may be repeated 1-2 times w/ intervals of 6-12 hr.
Click to view Octostim detailed prescribing infomation |
|
Contraindications |
Habitual or psychogenic polydipsia; unstable angina pectoris; decompensated cardiac insufficiency; von Willebrand's disease type IIB.
Click to view Octostim detailed prescribing infomation |
|
Special Precautions |
Avoid fluid overload & hyponatremia in the very young & elderly patient, conditions characterized by fluid &/or electrolyte imbalance, patient at risk of increased intracranial pressure & those requiring diuretic treatment.
Click to view Octostim detailed prescribing infomation |
|
Adverse Drug Reactions |
Fatigue, headache, nausea & stomach pain. At the time of administration, transient fall in BP w/ reflex tachycardia & facial flushing. Rarely, dizziness.
View ADR Monitoring Form |
|
Side Effects |
View Octostim side effects |
|
Drug Interactions |
Indomethacin may augment the magnitude but not the duration of the response to desmopressin.
View more drug interactions with Octostim |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Storage |
View Octostim storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Octostim description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Octostim mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
ATC Classification |
H01BA02 - desmopressin ; Belongs to the class of vasopressin and analogues. Used in posterior pituitary lobe hormone preparations. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Octostim injection |
|
Octostim 15 mcg/1 mL x 10's |
|
|
|
Manufacturer: |
Ferring |
|
Distributor: |
Hong Kong: Ferring
|
|
|
|
